News | August 15, 2024
Evonik expands its formulation capabilities for lipid nanoparticles
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
The new facility will accelerate the biotech and pharmaceutical industry's development by manufacturing vaccines, cell and gene therapies, and protein-based therapies
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Subscribe To Our Newsletter & Stay Updated
